Clinical Trial Update: EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating EGFR-TKI with concurrent or sequential chemotherapy in patients with lung adenocarcinoma harboring EGFR activating mutations after grad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Adenocarcinoma, EGFR Activating Mutation | Phase 2 | Status: COMPLETED